Review



tcrvb sequencing  (Adaptive Biotechnologies Corp)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Adaptive Biotechnologies Corp tcrvb sequencing
    Tcrvb Sequencing, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tcrvb+sequencing/high+throughput+tcr+dna+sequencing+immunoseq/pmc10208956-518-1-19
    Average 90 stars, based on 1 article reviews
    tcrvb sequencing - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Sequencing:

    Article Title: Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
    Article Snippet: .. The TCRVB sequencing results reported in this paper are available and can be accessed via the immuneACCESS database of Adaptive Biotechnologies ( https://clients.adaptivebiotech.com/pub/naghavian-2023-n ). .. The MS immunopeptidomic raw data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD036811 .



    Similar Products

    tcrvb sequencing  (Adaptive Biotechnologies Corp)
    90
    Adaptive Biotechnologies Corp tcrvb sequencing
    Tcrvb Sequencing, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tcrvb+sequencing/high+throughput+tcr+dna+sequencing+immunoseq/pmc10208956-518-1-19
    Average 90 stars, based on 1 article reviews
    tcrvb sequencing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    t-cell receptor vb (tcrvb) deep sequencing  (Adaptive Biotechnologies Corp)
    90
    Adaptive Biotechnologies Corp t-cell receptor vb (tcrvb) deep sequencing
    T Cell Receptor Vb (Tcrvb) Deep Sequencing, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tcrvb+sequencing/t+cell+receptor+vb++tcrvb++deep+sequencing/pm36843851-296-10-18
    Average 90 stars, based on 1 article reviews
    t-cell receptor vb (tcrvb) deep sequencing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    t-cell receptor vβ (tcrvb) deep sequencing  (Adaptive Biotechnologies Corp)
    90
    Adaptive Biotechnologies Corp t-cell receptor vβ (tcrvb) deep sequencing
    PTCy eradicates the most xenoreactive clones NSG mice were injected with 2 × 10 7 hPBMC and treated (n = 10) or not (n = 10) with PTCy (100 mg/kg) on day three. Mice were sacrificed on day 21 for harvesting CD4 + and CD8 + T cells from the spleen and lungs. DNA was extracted and <t>TCRVB</t> <t>sequencing</t> analysis was performed. (A) Productive clonality (higher clonality indicates a less diverse repertoire) of CD4 + and CD8 + T cells between the donor (before infusion to mice) and spleen/lungs from control mice. (B) Productive clonality of CD4 + and CD8 + T cells from the spleen and lung between control and PTCy-treated mice. (C) Heatmap of clonotypes overlap between samples calculated by Morista index for CD4 + T cells (left panel) and CD8 + T cells (right panel). (D) Proportion of CD4 + and CD8 + clonotypes upregulated (Up, = xenoreactive clonotypes) and clonotypes downregulated (Down, = bystanders) in control found in PTCy-treated mice. (E) Proportion of CD4 + and CD8 + clonotypes upregulated in spleen/lungs from control vs donor or from treated vs donor. (F) Frequency of CD4 + and CD8 + xenoreactive clonotypes from the spleen/lungs shared between control and PTCy-treated mice. Data show median values with min to max for boxplot. (∗p ≤ 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). See also <xref ref-type=Figure S6 . " width="250" height="auto" />
    T Cell Receptor Vβ (Tcrvb) Deep Sequencing, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tcrvb+sequencing/t+cell+receptor+v%CE%B2++tcrvb++deep+sequencing/pmc09947306-379-10-18
    Average 90 stars, based on 1 article reviews
    t-cell receptor vβ (tcrvb) deep sequencing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    primary tcrvb sequencing data  (Adaptive Biotechnologies Corp)
    90
    Adaptive Biotechnologies Corp primary tcrvb sequencing data
    PTCy eradicates the most xenoreactive clones NSG mice were injected with 2 × 10 7 hPBMC and treated (n = 10) or not (n = 10) with PTCy (100 mg/kg) on day three. Mice were sacrificed on day 21 for harvesting CD4 + and CD8 + T cells from the spleen and lungs. DNA was extracted and <t>TCRVB</t> <t>sequencing</t> analysis was performed. (A) Productive clonality (higher clonality indicates a less diverse repertoire) of CD4 + and CD8 + T cells between the donor (before infusion to mice) and spleen/lungs from control mice. (B) Productive clonality of CD4 + and CD8 + T cells from the spleen and lung between control and PTCy-treated mice. (C) Heatmap of clonotypes overlap between samples calculated by Morista index for CD4 + T cells (left panel) and CD8 + T cells (right panel). (D) Proportion of CD4 + and CD8 + clonotypes upregulated (Up, = xenoreactive clonotypes) and clonotypes downregulated (Down, = bystanders) in control found in PTCy-treated mice. (E) Proportion of CD4 + and CD8 + clonotypes upregulated in spleen/lungs from control vs donor or from treated vs donor. (F) Frequency of CD4 + and CD8 + xenoreactive clonotypes from the spleen/lungs shared between control and PTCy-treated mice. Data show median values with min to max for boxplot. (∗p ≤ 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). See also <xref ref-type=Figure S6 . " width="250" height="auto" />
    Primary Tcrvb Sequencing Data, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tcrvb+sequencing/high+throughput+tcr+dna+sequencing+immunoseq/pm35413271-331-2-11
    Average 90 stars, based on 1 article reviews
    primary tcrvb sequencing data - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    tcrvb sequencing data  (Adaptive Biotechnologies Corp)
    86
    Adaptive Biotechnologies Corp tcrvb sequencing data
    PTCy eradicates the most xenoreactive clones NSG mice were injected with 2 × 10 7 hPBMC and treated (n = 10) or not (n = 10) with PTCy (100 mg/kg) on day three. Mice were sacrificed on day 21 for harvesting CD4 + and CD8 + T cells from the spleen and lungs. DNA was extracted and <t>TCRVB</t> <t>sequencing</t> analysis was performed. (A) Productive clonality (higher clonality indicates a less diverse repertoire) of CD4 + and CD8 + T cells between the donor (before infusion to mice) and spleen/lungs from control mice. (B) Productive clonality of CD4 + and CD8 + T cells from the spleen and lung between control and PTCy-treated mice. (C) Heatmap of clonotypes overlap between samples calculated by Morista index for CD4 + T cells (left panel) and CD8 + T cells (right panel). (D) Proportion of CD4 + and CD8 + clonotypes upregulated (Up, = xenoreactive clonotypes) and clonotypes downregulated (Down, = bystanders) in control found in PTCy-treated mice. (E) Proportion of CD4 + and CD8 + clonotypes upregulated in spleen/lungs from control vs donor or from treated vs donor. (F) Frequency of CD4 + and CD8 + xenoreactive clonotypes from the spleen/lungs shared between control and PTCy-treated mice. Data show median values with min to max for boxplot. (∗p ≤ 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). See also <xref ref-type=Figure S6 . " width="250" height="auto" />
    Tcrvb Sequencing Data, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tcrvb+sequencing/data+sequencing+tcrvb/pmc09011147-543-2-11
    Average 86 stars, based on 1 article reviews
    tcrvb sequencing data - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dna isolation and tcrvb sequencing  (Adaptive Biotechnologies Corp)
    90
    Adaptive Biotechnologies Corp dna isolation and tcrvb sequencing
    PTCy eradicates the most xenoreactive clones NSG mice were injected with 2 × 10 7 hPBMC and treated (n = 10) or not (n = 10) with PTCy (100 mg/kg) on day three. Mice were sacrificed on day 21 for harvesting CD4 + and CD8 + T cells from the spleen and lungs. DNA was extracted and <t>TCRVB</t> <t>sequencing</t> analysis was performed. (A) Productive clonality (higher clonality indicates a less diverse repertoire) of CD4 + and CD8 + T cells between the donor (before infusion to mice) and spleen/lungs from control mice. (B) Productive clonality of CD4 + and CD8 + T cells from the spleen and lung between control and PTCy-treated mice. (C) Heatmap of clonotypes overlap between samples calculated by Morista index for CD4 + T cells (left panel) and CD8 + T cells (right panel). (D) Proportion of CD4 + and CD8 + clonotypes upregulated (Up, = xenoreactive clonotypes) and clonotypes downregulated (Down, = bystanders) in control found in PTCy-treated mice. (E) Proportion of CD4 + and CD8 + clonotypes upregulated in spleen/lungs from control vs donor or from treated vs donor. (F) Frequency of CD4 + and CD8 + xenoreactive clonotypes from the spleen/lungs shared between control and PTCy-treated mice. Data show median values with min to max for boxplot. (∗p ≤ 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). See also <xref ref-type=Figure S6 . " width="250" height="auto" />
    Dna Isolation And Tcrvb Sequencing, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tcrvb+sequencing/dna+isolation+and+tcrvb+sequencing/pm31685621-275-3-8
    Average 90 stars, based on 1 article reviews
    dna isolation and tcrvb sequencing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    tcrvb high-throughput sequencing  (Adaptive Biotechnologies Corp)
    90
    Adaptive Biotechnologies Corp tcrvb high-throughput sequencing
    PTCy eradicates the most xenoreactive clones NSG mice were injected with 2 × 10 7 hPBMC and treated (n = 10) or not (n = 10) with PTCy (100 mg/kg) on day three. Mice were sacrificed on day 21 for harvesting CD4 + and CD8 + T cells from the spleen and lungs. DNA was extracted and <t>TCRVB</t> <t>sequencing</t> analysis was performed. (A) Productive clonality (higher clonality indicates a less diverse repertoire) of CD4 + and CD8 + T cells between the donor (before infusion to mice) and spleen/lungs from control mice. (B) Productive clonality of CD4 + and CD8 + T cells from the spleen and lung between control and PTCy-treated mice. (C) Heatmap of clonotypes overlap between samples calculated by Morista index for CD4 + T cells (left panel) and CD8 + T cells (right panel). (D) Proportion of CD4 + and CD8 + clonotypes upregulated (Up, = xenoreactive clonotypes) and clonotypes downregulated (Down, = bystanders) in control found in PTCy-treated mice. (E) Proportion of CD4 + and CD8 + clonotypes upregulated in spleen/lungs from control vs donor or from treated vs donor. (F) Frequency of CD4 + and CD8 + xenoreactive clonotypes from the spleen/lungs shared between control and PTCy-treated mice. Data show median values with min to max for boxplot. (∗p ≤ 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). See also <xref ref-type=Figure S6 . " width="250" height="auto" />
    Tcrvb High Throughput Sequencing, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tcrvb+sequencing/high+throughput+tcr+dna+sequencing+immunoseq/10__1159_slash_000449050-3721-27-34
    Average 90 stars, based on 1 article reviews
    tcrvb high-throughput sequencing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    PTCy eradicates the most xenoreactive clones NSG mice were injected with 2 × 10 7 hPBMC and treated (n = 10) or not (n = 10) with PTCy (100 mg/kg) on day three. Mice were sacrificed on day 21 for harvesting CD4 + and CD8 + T cells from the spleen and lungs. DNA was extracted and TCRVB sequencing analysis was performed. (A) Productive clonality (higher clonality indicates a less diverse repertoire) of CD4 + and CD8 + T cells between the donor (before infusion to mice) and spleen/lungs from control mice. (B) Productive clonality of CD4 + and CD8 + T cells from the spleen and lung between control and PTCy-treated mice. (C) Heatmap of clonotypes overlap between samples calculated by Morista index for CD4 + T cells (left panel) and CD8 + T cells (right panel). (D) Proportion of CD4 + and CD8 + clonotypes upregulated (Up, = xenoreactive clonotypes) and clonotypes downregulated (Down, = bystanders) in control found in PTCy-treated mice. (E) Proportion of CD4 + and CD8 + clonotypes upregulated in spleen/lungs from control vs donor or from treated vs donor. (F) Frequency of CD4 + and CD8 + xenoreactive clonotypes from the spleen/lungs shared between control and PTCy-treated mice. Data show median values with min to max for boxplot. (∗p ≤ 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). See also <xref ref-type=Figure S6 . " width="100%" height="100%">

    Journal: iScience

    Article Title: Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells

    doi: 10.1016/j.isci.2023.106085

    Figure Lengend Snippet: PTCy eradicates the most xenoreactive clones NSG mice were injected with 2 × 10 7 hPBMC and treated (n = 10) or not (n = 10) with PTCy (100 mg/kg) on day three. Mice were sacrificed on day 21 for harvesting CD4 + and CD8 + T cells from the spleen and lungs. DNA was extracted and TCRVB sequencing analysis was performed. (A) Productive clonality (higher clonality indicates a less diverse repertoire) of CD4 + and CD8 + T cells between the donor (before infusion to mice) and spleen/lungs from control mice. (B) Productive clonality of CD4 + and CD8 + T cells from the spleen and lung between control and PTCy-treated mice. (C) Heatmap of clonotypes overlap between samples calculated by Morista index for CD4 + T cells (left panel) and CD8 + T cells (right panel). (D) Proportion of CD4 + and CD8 + clonotypes upregulated (Up, = xenoreactive clonotypes) and clonotypes downregulated (Down, = bystanders) in control found in PTCy-treated mice. (E) Proportion of CD4 + and CD8 + clonotypes upregulated in spleen/lungs from control vs donor or from treated vs donor. (F) Frequency of CD4 + and CD8 + xenoreactive clonotypes from the spleen/lungs shared between control and PTCy-treated mice. Data show median values with min to max for boxplot. (∗p ≤ 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). See also Figure S6 .

    Article Snippet: One hundred fifty μg from each sample were used for T-cell receptor Vβ (TCRVB) deep sequencing performed by Adaptive Biotechnologies (Seattle, Washington, WA, USA).

    Techniques: Clone Assay, Injection, Sequencing, Control

    Journal: iScience

    Article Title: Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells

    doi: 10.1016/j.isci.2023.106085

    Figure Lengend Snippet:

    Article Snippet: One hundred fifty μg from each sample were used for T-cell receptor Vβ (TCRVB) deep sequencing performed by Adaptive Biotechnologies (Seattle, Washington, WA, USA).

    Techniques: Staining, Recombinant, Activation Assay, Red Blood Cell Lysis, Cell Isolation, Selection, Flow Cytometry, Luminex, Cell Stimulation, Sequencing, Isolation, Transduction, Luciferase, Expressing, Software, Imaging